178 related articles for article (PubMed ID: 36401126)
1. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
Wang Z; Yan X; Tang P; Tang T; Wang Y; Peng S; Wang S; Lan W; Wang L; Zhang Y; Zhang J; Li K; Shu Z; Xu J; Qin J; Zhang D; Jiang J; Liu Q
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):180-187. PubMed ID: 36401126
[TBL] [Abstract][Full Text] [Related]
2. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
[TBL] [Abstract][Full Text] [Related]
4. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.
Daniel M; Knutson TP; Sperger JM; Li Y; Singh A; Stahlfeld CN; Passow C; Auch B; Lang JM; Dehm SM
Endocr Relat Cancer; 2021 Aug; 28(9):645-655. PubMed ID: 34280123
[TBL] [Abstract][Full Text] [Related]
5. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract][Full Text] [Related]
6. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
[TBL] [Abstract][Full Text] [Related]
8. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T; Mizuno K; Yamasaki T; Miyazaki Y; Makino Y; Okasho K; Li X; Utsunomiya N; Goto T; Kobayashi T; Terada N; Inoue T; Kamba T; Fujimoto A; Ogawa O; Akamatsu S
Sci Rep; 2019 Mar; 9(1):4030. PubMed ID: 30858508
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
11. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal Instability in Cell-free DNA as a Prognostic Biomarker of Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy.
Lee CU; Cho E; Lee J; Lim JE; Chung JH; Song W; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Eur Urol Focus; 2023 Jan; 9(1):89-95. PubMed ID: 36167777
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Hendriks RJ; Dijkstra S; Smit FP; Vandersmissen J; Van de Voorde H; Mulders PFA; van Oort IM; Van Criekinge W; Schalken JA
Prostate; 2018 Apr; 78(5):336-342. PubMed ID: 29330943
[TBL] [Abstract][Full Text] [Related]
14. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
[TBL] [Abstract][Full Text] [Related]
16. Practical Utility of Liquid Biopsies for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer.
Jeong SH; Kyung D; Yuk HD; Jeong CW; Lee W; Yoon JK; Kim HP; Bang D; Kim TY; Lim Y; Kwak C
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345184
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
20. Distinct Metabolic Signatures of Hormone-Sensitive and Castration-Resistant Prostate Cancer Revealed by a
Zheng H; Zhu Y; Shao X; Cai A; Dong B; Xue W; Gao H
J Proteome Res; 2020 Sep; 19(9):3741-3749. PubMed ID: 32702989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]